Last 638.20 INR
Change Today +5.40 / 0.85%
Volume 62.0K
PIEL On Other Exchanges
Symbol
Exchange
Natl India
As of 7:06 AM 07/24/14 All times are local (Market data is delayed by at least 15 minutes).

piramal enterprises ltd (PIEL) Snapshot

Open
639.25
Previous Close
632.80
Day High
646.50
Day Low
627.30
52 Week High
07/3/14 - 791.00
52 Week Low
11/26/13 - 475.25
Market Cap
110.1B
Average Volume 10 Days
83.2K
EPS TTM
-29.06
Shares Outstanding
172.6M
EX-Date
07/15/14
P/E TM
--
Dividend
52.50
Dividend Yield
8.23%
Current Stock Chart for PIRAMAL ENTERPRISES LTD (PIEL)

Related News

No related news articles were found.

piramal enterprises ltd (PIEL) Related Businessweek News

No Related Businessweek News Found

piramal enterprises ltd (PIEL) Details

Piramal Enterprises Limited primarily manufactures and sells own and traded bulk drugs and formulations in India and internationally. It operates through three segments: Pharmaceuticals Businesses, Financial Services Businesses, and Information Management Business. The company provides custom manufacturing services across the entire drug lifecycle ranging from development and commercial manufacturing to off-patent supplies of active pharmaceutical ingredients and formulations. It also manufactures and sells inhalation anaesthetics, such as Halothane, Isoflurane, and Sevoflurane; Propofol; and plasma volume expanders, including Polygeline. In addition, the company offers vitamins and nutrition, analgesics, dermatological, antacids, and cough and cold products under various brands, such as Saridon, Lacto Calamine, i-Pill, Itchmosol, Supractiv Complete, Polycrol, i-Sure, i-Can, Jungle Magic, Tetmosol, and Triactiv; and lipids and immunoturbidimetric HbA1c kits to bio-chemistry analysers, hematology analysers, and diasys range of reagents. Further, it develops various medicines that are in Phase I trials comprising GPR40 agonist - P11187, an oral anti-diabetic molecule; P7435, a DGAT1 inhibitor that addresses multiple aspects of metabolic syndrome; and P1446 and P7170 for oncology. Additionally, the company offers Neuraceq, an imaging agent; BST-CarGel, a bio-scaffold for cartilage regeneration; and focuses on the research and commercialization of natural products and herbal medicines. It also offers finance to real estate developers; structured finance transaction services for infrastructure companies; and data analytics services to pharmaceutical, medical device, managed care, and other healthcare industry customers, as well as is engaged in NBFC operations. The company was formerly known as Piramal Healthcare Limited and changed its name to Piramal Enterprises Limited in July 2012. Piramal Enterprises Limited was incorporated in 1947 and is based in Mumbai, India.

4,984 Employees
Last Reported Date: 06/26/14
Founded in 1947

piramal enterprises ltd (PIEL) Top Compensated Officers

Chairman, Member of Nomination & Remuneration...
Total Annual Compensation: 63.0M
Chief Operating Officer, Executive Director a...
Total Annual Compensation: 35.3M
Vice Chairperson and Director of Strategic Al...
Total Annual Compensation: 30.1M
General Manager of Strategic Marketing, Execu...
Total Annual Compensation: 21.3M
Compensation as of Fiscal Year 2014.

piramal enterprises ltd (PIEL) Key Developments

Piramal In Negotiations To Acquire Projects

Piramal Enterprises Limited (BSE:500302) is in advanced negotiations to acquire two more projects.

Piramal Enterprises Mulls Acquisitions In Operational Road Projects

Piramal Enterprises Limited (BSE:500302) is planning an investment of INR 5000 crore in infrastructure projects like road, power and renewable energy by 2016. It is likely to finalise some deals shortly. Piramal Enterprises has already invested INR 425 crore in Navayuga Road Projects Pvt Ltd of Hyderabad and INR 500 crore in Green Infra Ltd. It is also interested in acquiring Operational Road Projects.

Piramal Enterprises Limited Reports Audited Standalone and Consolidated Earnings Results for the Fourth Quarter and Year Ended March 31, 2014

Piramal Enterprises Limited reported audited standalone and consolidated earnings results for the fourth quarter and year ended March 31, 2014. For the quarter, on consolidated basis, the company reported total income from operations (net) of INR 11,209.9 million against INR 9,386.1 million, profit from operations before other income, other income, finance cost and exceptional items of INR 57.8 million against INR 394.8 million, loss from ordinary activities before tax of INR 2,832.9 million against INR 1,909.7 million and net loss after taxes, minority interest and share of loss of associates of INR 3,113.5 million or INR 18.1 per basic and diluted share against INR 2,004.1 million or INR 11.6 per basic and diluted share a year ago. For the year, on consolidated basis, the company reported total income from operations (net) of INR 45,201.6 million against INR 35,443.3 million, profit from operations before other income, other income, finance cost and exceptional items of INR 4,096.1 million against INR 2,463.0 million, loss from ordinary activities before tax of INR 4,347.7 million against INR 1,927.2 million and net loss after taxes, minority interest and share of loss of associates of INR 5,014.1 million or INR 29.1 per basic and diluted share against INR 2,272.9 million or INR 13.2 per basic and diluted share a year ago. For the quarter, on standalone basis, the company reported total income from operations (net) of INR 5,447.1 million against INR 4,333.8 million, profit from operations before other income, other income, finance cost and exceptional items of INR 360.6 million against INR 129.3 million, loss from ordinary activities before tax of INR 2,013.9 million against INR 1,596.8 million and net loss of INR 2,013.9 million or INR 11.6 per basic and diluted share against INR 1,521.7 million or INR 8.8 per basic and diluted share a year ago. For the year, on standalone basis, the company reported total income from operations (net) of INR 20,930.8 million against INR 16,180.9 million, profit from operations before other income, other income, finance cost and exceptional items of INR 2,377.2 million against INR 109.8 million, loss from ordinary activities before tax of INR 3,700.0 million against INR 2,478.8 million and net loss of INR 3,700.0 million or INR 21.4 per basic and diluted share against INR 2,315.6 million or INR 13.4 per basic and diluted share a year ago.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PIEL:IN 638.20 INR +5.40

PIEL Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Biocon Ltd 517.90 INR +4.75
Divi's Laboratories Ltd 1,500 INR +21.80
Jubilant Life Sciences Ltd 189.40 INR -4.05
Sanofi India Ltd 3,000 INR +56.50
Torrent Pharmaceuticals Ltd 689.95 INR -9.80
View Industry Companies
 

Industry Analysis

PIEL

Industry Average

Valuation PIEL Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 2.4x
Price/Book 1.2x
Price/Cash Flow NM Not Meaningful
TEV/Sales 0.2x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PIRAMAL ENTERPRISES LTD, please visit www.piramal.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.